GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kiniksa Pharmaceuticals International KNSA · USD

Health Care · US listing · 🇺🇸 United States

Compare

93.90

+0.38%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Kiniksa Pharmaceuticals International — daily KNSA Delayed
Market value
$7.42bn
Last close × shares
Volume
545.2k
Shares, 20 Nov 2026
Price to earnings
128.7

About Kiniksa Pharmaceuticals International

From its filings with the US Securities and Exchange Commission

SEC filings

Kiniksa Pharmaceuticals International is based in London. Its shares trade on Nasdaq under the ticker KNSA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $677.6m and net income of $59.0m. At that date it held total assets of $763.6m and shareholders' equity of $567.6m.

In its own words

We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.

ARCALYST is an interleukin-1α (“IL-1α”) and interleukin-1β (“IL-1β”) cytokine trap. In 2017, we licensed ARCALYST from Regeneron, which discovered and initially developed the drug. Our exclusive license to ARCALYST from Regeneron includes worldwide rights, excluding the Middle East and North Africa, for all applications other than those in oncology and local administration to the eye or ear.

We received FDA approval of ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older in March 2021. Recurrent pericarditis is a painful inflammatory cardiovascular disease with an estimated United States prevalent population of approximately 40,000 patients seeking and receiving medical treatment. ARCALYST is also approved in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (“CAPS”), including Familial Cold Autoinflammatory Syndrome (“FCAS”) and Muckle-Wells Syndrome in adults and children 12 years and older, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist (“DIRA”) in adults and children weighing 10 kg or more.

Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗

More about Kiniksa Pharmaceuticals International →

Latest on Kiniksa Pharmaceuticals International

Our reporting

Next results

23 Feb 2027

Due on 23 Feb 2027. Analysts expect earnings of 0.29 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Kiniksa Pharmaceuticals International's ticker?

Kiniksa Pharmaceuticals International trades as KNSA on its US listing, under ISIN GB00BRXB0C07.

What was Kiniksa Pharmaceuticals International's last closing price?

93.90 on 20 Nov 2026. The figure is in USD and is never converted.

When does Kiniksa Pharmaceuticals International next report results?

Results are expected on 23 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.